Compare · OMCL vs XNDU
OMCL vs XNDU
Side-by-side comparison of Omnicell Inc. (OMCL) and Xanadu Quantum Technologies Limited (XNDU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OMCL and XNDU operate in Computer Manufacturing (Technology), so they compete in similar markets.
- XNDU is the larger of the two at $3.85B, about 2.0x OMCL ($1.96B).
- Over the past year, OMCL is up 35.9% and XNDU is up 33.1% - OMCL leads by 2.8 points.
- OMCL has been more active in the news (16 items in the past 4 weeks vs 8 for XNDU).
- OMCL has more recent analyst coverage (24 ratings vs 2 for XNDU).
- Company
- Omnicell Inc.
- Xanadu Quantum Technologies Limited
- Price
- $43.04+0.07%
- $13.27+2.51%
- Market cap
- $1.96B
- $3.85B
- 1M return
- -0.72%
- -23.47%
- 1Y return
- +35.86%
- +33.10%
- Industry
- Computer Manufacturing
- Computer Manufacturing
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- News (4w)
- 16
- 8
- Recent ratings
- 24
- 2
Omnicell Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Latest OMCL
- Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
- Director Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)
- Director Scott Bruce E was granted 4,627 shares, increasing direct ownership by 20% to 27,600 units (SEC Form 4)
- Director Seim Robin Gene was granted 4,845 shares, increasing direct ownership by 10% to 52,198 units (SEC Form 4)
- Director Voynick Eileen J. was granted 4,785 shares, increasing direct ownership by 31% to 20,011 units (SEC Form 4)
- Director Parrish Mark W was granted 4,845 shares, increasing direct ownership by 7% to 70,100 units (SEC Form 4)
- Director Bauer Joanne B was granted 5,027 shares, increasing direct ownership by 11% to 49,922 units (SEC Form 4)
- Director Garrett Mary was granted 5,027 shares, increasing direct ownership by 29% to 22,202 units (SEC Form 4)
- Director Ghoshal Kaushik was granted 4,603 shares, increasing direct ownership by 32% to 19,123 units (SEC Form 4)
- Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Latest XNDU
- SEC Form EFFECT filed by Xanadu Quantum Technologies Limited
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited
- SEC Form S-8 filed by Xanadu Quantum Technologies Limited
- SEC Form F-1 filed by Xanadu Quantum Technologies Limited
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited
- SEC Form 6-K filed by Xanadu Quantum Technologies Limited
- Xanadu breakthrough lowers the cost of quantum applications
- Xanadu Announces $300 Million Synthetic At-The-Market Program
- Amendment: SEC Form SCHEDULE 13G/A filed by Xanadu Quantum Technologies Limited
- SEC Form 424B3 filed by Xanadu Quantum Technologies Limited